{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:35:59Z","timestamp":1785440159777,"version":"3.56.0"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Dobutamine (DB) is a \u03b21\u2010adrenergic agonist with weak \u03b22 activity and\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/en.wikipedia.org\/wiki\/Alpha-1_receptor\">\u03b11<\/jats:ext-link>\n                    selective activity, which is used clinically in cases of cardiogenic shock. Most of the available literature methods for DB that are LCMS incompatible have limitations for the identification of impurities. The current study describes forced degradation studies of DB and the identification of impurities by mass analysis, assigning structure to the major degradant, and the development and validation of an LCMS\u2010compatible UPLC method. Impurity A (dopamine) highly polar impurity listed in the dopamine US Pharmacopeial Monograph, was retained in the developed method without an ion pair reagent. The method has been developed using Waters Acquity UPLC system equipped with Acquity UPLC HSS PFP column (2.1\u2009mm\u2009\u00d7\u2009100\u2009mm, 1.8\u2009\u03bc), 0.05% TFA in water:ACN (95:5 %v\/v) as Mobile Phase A, and 0.05% TFA in water:ACN (5:95 %v\/v) as Mobile Phase B using a gradient program. DB degradation behavior was studied by subjecting it to acidic, basic, neutral, and oxidative conditions as per ICH guideline Q1A (R2). One of the major degradants was isolated by preparative HPLC and identified characterization by LCMS\/MS and HRMS. The newly developed UPLC method was found to be specific with respect to degradation products, and the method has been validated according to the ICH guidelines.\n                  <\/jats:p>","DOI":"10.1002\/bmc.70211","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T02:38:56Z","timestamp":1762137536000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Forced Degradation Studies of Dobutamine and Isolation, Identification, and Characterization of Potential Degradation Impurity by Preparative HPLC, LC\u2013MS\/MS. Development and Validation of Stability Indicative UPLC Method"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1272-1524","authenticated-orcid":false,"given":"Babu\u00a0Reddy","family":"Goguladinne","sequence":"first","affiliation":[{"name":"Aragen Life Sciences PVT Limited  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pulipaka","family":"Shyamala","sequence":"additional","affiliation":[{"name":"Department of Chemistry Andhra University  Visakhapatnam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.\u00a0M.\u00a0V.\u00a0Narayana","family":"Rao","sequence":"additional","affiliation":[{"name":"Aragen Life Sciences PVT Limited  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"60","article-title":"A Stress Testing Benchmarking Study","volume":"27","author":"Alsante K. M.","year":"2003","journal-title":"Pharmaceutical Technology"},{"key":"e_1_2_9_3_1","volume-title":"Pharmaceutical Stress Testing: Predicting Drug Degradation","author":"Baertschi S. W.","year":"2011"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1721"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3ay40804c"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5424"},{"key":"e_1_2_9_7_1","volume-title":"Note for Guidance on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products","author":"CPMP","year":"2002"},{"issue":"4","key":"e_1_2_9_8_1","first-page":"686","article-title":"Stability of Dobutamine Hydrochloride and Verapamil Hydrochloride in 0.9% Sodium Chloride and 5% Dextrose Injections","volume":"41","author":"Das Gupta V.","year":"1984","journal-title":"American Journal of Hospital Pharmacy"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102021\u2010002748"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202300106"},{"issue":"6","key":"e_1_2_9_11_1","first-page":"1234","article-title":"Stability of Dobutamine Hydrochloride in Peritoneal Dialysis Solutions","volume":"48","author":"Gora M. L.","year":"1991","journal-title":"American Journal of Hospital Pharmacy"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2006.05.011"},{"key":"e_1_2_9_13_1","volume-title":"Stability Testing of New Drug Substances and Products Q1A (R2)","author":"ICH","year":"2003"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1351\/PAC\u2010REC\u201006\u201004\u201006"},{"issue":"1","key":"e_1_2_9_15_1","first-page":"73","article-title":"Stability of Zidovudine and Dobutamine Hydrochloride Injections in 0.9% Sodium Chloride and 5% Dextrose Injections Stored at Ambient Temperature (23 +\/\u2212 2 Deg C) and 4 Deg C in 50\u2010mL Polyvinyl Chloride Bags Up to 24 Hours","volume":"8","author":"Musami P.","year":"2004","journal-title":"International Journal of Pharmaceutical Compounding"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.08.052"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm\u20102011\u2010000027"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.06.021"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.3403"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.11.008"},{"key":"e_1_2_9_21_1","volume-title":"Guidance for Industry Stability Testing of Existing Drug Substances and Products","author":"TPD","year":"2003"},{"issue":"5","key":"e_1_2_9_22_1","article-title":"Dobutamine Hydrochloride","volume":"29","author":"USP Monographs","year":"2023","journal-title":"Pharmacopeial Forum"},{"issue":"5","key":"e_1_2_9_23_1","first-page":"412","article-title":"Stability of Dobutamine Hydrochloride 4mg\/mL in 5% Dextrose Injection at 5 and 23 Deg C","volume":"3","author":"Webster A. A.","year":"1999","journal-title":"International Journal of Pharmaceutical Compounding"},{"key":"e_1_2_9_24_1","unstructured":"WHO.2018. \u201cGuidelines on Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products.\u201d"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1695"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T12:52:38Z","timestamp":1764420758000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,2]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/bmc.70211"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70211","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,2]]},"assertion":[{"value":"2025-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70211"}}